Drugs / NUV-422
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04541225 | Dec 2020 → Aug 2022 | breast carcinoma, castration-resistant prostate carcinoma, glioblastoma, mixed glioma | Nuvation Bio Inc. | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05191017 | Sep 2022 → Jan 2025 | prostate carcinoma | Nuvation Bio Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05191004 | Sep 2022 → Jun 2025 | breast carcinoma | Nuvation Bio Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUV-422 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05191004 ↗ |
| Route | Oral | “self-administered NUV-422 orally” NCT04541225 ↗ |